Licensure, Tennessee Panel of Medical Investigators, Dec 3, 1991 (#Maryland-022045). Accreditation, National Board of Medical Investigators, March 7, 1990 (#358278).
Accreditation, National Board of Psychiatry and Neurology, May 1996 (#42783) HEALTHCARE COMMITTEES AND HONORS: Guy, National Headache Society
Guide Publisher, Frustration, July 2001 to provide. Content Board of Frustration, associate, July 2001 to provide. Associate, Medical Society, Alpha Leader, chosen 1991.
American Association, associate. Tennessee Association, associate. Nashville School of Medication, associate. Associate (energetic), National Academy of Neurology.
Associate, National Headache Culture, presently on Ethics Panel. 1998, associate, Review Panel, National Organization for that Research of Frustration.
Ny, advisor, Coordinating Committee, 10th Congress of the Worldwide Headache Culture, Ny, July 29. Associate, Board, National Authority for Frustration Training (PAIN), 2001-present.
LABYRINTH Individual Study, Steering Committee, September 2000. Vanderbilt Alumni, Advisory Board Nashville Panel of Administrators
Associate, Vanderbilt Medical School 1996-97, Academic Panel. Called to Best Physicians within the Midwest, 1998-99, 1996-97
Sanofi Recherche, principal Researcher, Clopidogrel EFC4505, 2002. Severe Treatment of Migraine, principal Investigator Nasal Spray,
311CUS/ AstraZeneca, 0022, 2002. GlaxoSmithKline, principal Investigator Nasal Spray SUM30045, 2002.
Principal Researcher, Migraines, Sumatriptan GlaxoSmithKline Novartis Prophylactic Treatment,
Principal Researcher, Allergan, Prophylactic Therapy of Migraine Headache, 191622- 037-01, 2002 – 2003. Principal Researcher, Allergan, Prophylactic Therapy of Serious Headache Populace, 191622-038-02, 2002-2003.
Principal Pfizer Therapy of Migraine A1601080, 2002. Principal Investigator ZMT Therapy 311CUS/0016, of Migraine,
Principal Sumatriptan Therapy of Migraine GlaxoSmithKline, 2002. Principal Lamotrigine Researcher or Valproate, PCOS in feminine subjects with recently
LAM30007, epilepsy, GlaxoSmithKline. Principal Investigator Administration of Sanofi- 2002, Synthelabo, COMPLEMENT.
Principal Civamide Therapy of Group Frustration, Winston Inc., WL-1001-02-02, 2002. Principal Sumatriptan Therapy of Menstrually Related Migraine
Throughout the Moderate Stage, SUM40285, GlaxoSmithKline, 2001-2002. Principal Myobloc Information (BRAIN) Registry, 2001-2002, Elan Pharmaceuticals.
Merck, principal Researcher, Rofecoxib 161-00, 2001. Principal Sumatriptan Therapy Teenage Test, of Migraine,
Glaxo – Wellcome. MK0462 – 061, principal Researcher, Rizatriptan Therapy of Migraine in Teenagers, Merck, 2001.
Principal Researcher, Sumatriptan – 2001, Migraine Assault, GlaxoSmithKline. Principal Levetiracetam Therapy of N01014,
Pharma, 2001, Inc.. Prophylaxis of Migraine, principal Researcher, Topiramate, TOPMAT-MIGR-002,
Principal Zolmitriptan Therapy 311CUS/0015, of Migraine,
Principal Researcher, Sumatriptan Treatment SUM40274, of Pain / 2000, SUM40275 SUM40276 Wellcome. Principal Montelukast Researcher Prophylaxis of Episodes,
125-00, Co. Merck & April 2000. Topiramate, principal Researcher, Therapy of Neuropathy Discomfort, PRI BEST/INT/24, R. WATTS. 2000, Brown.
Principal Frustration Evaluation Research in Primary-Care, Researcher Pfizer,
Principal May, Investigator S2W40027 Wellcome
S2W40012, principal Amerge Migraine Research Wellcome, Dec 1999-2000. Prophylaxis in Headache Episodes, principal Researcher, Dental GV196771,
Glaxo- Wellcome. Principal Botox Therapy of Migraine, 191622-024-00- 1916222-026-00, Allergan.
Principal Researcher, Rizatriptan Migraine Research, Merck MAX478 Inc., Oct 1999. S2WA4006, principal Naratriptan Migraine Research, Glaxo
Principal Researcher, Bristol-Myers Dose-Response Test of BMS, Squibb -204352 June 1998-99, in Severe Swing. Denver-Detective, Worldwide, Multi Center, Randomized Party Research of GV 150526 in
Treating Acute Stroke of Sufferers having a Medical Analysis
Principal Naratriptan Migraine Study – 3012
Denver- Detective, ANCROD Swing Test, Collaborative Research through St Thomas Clinic and University Clinic, 1993-1994.
Denver- Vanderbilt Medical, Investigator Plasminogen Test
AFFILIATIONS: Nashville, Baptist Hospital, Tn. Nashville, Centennial Clinic, Tn. Nashville, St Thomas Clinic, Tn.
Nashville, University Clinic, Tn. Rehabilitation Hospital, Nashville, Vanderbilt Clinic, Tn.
Nashville, Veteran’s Management Clinic, Tn. College of Tn, pREVIOUS EXPERIENCE Manager, Tennessee Research Centre, Knoxville, Tn. 1980-82.
College of Tn, Research Associate, Division of Microbiology, Knoxville,Tn. 1978-80. College of Tn, Teaching Associate, Division of Microbiology, Knoxville, Tn. 1977-78.
Tupelo, overseer of Publicrelations, Northern Mississippi Clinic, Mississippi. 1975-77.
National Glaxo-Wellcome. Nationwide Speaker’s Agency, Merck AstraZeneca Nationwide Speaker’s Agency Inc.
Nationwide Speaker’s Agency, Allergan Nationwide Speaker’s Agency, Pfizer Nationwide Speaker’s Agency, Pharmacia Nationwide Speaker’s Agency, ortho mcneil
Faculty Ambassador System. Migraine Plan, nationwide Advisor, backed by Glaxo-Wellcome. 1997-98. Headaches Management, The College of New York, and Hill Faculty of Nursing.
Nov 6, “Women’s Problems and Migraine” College of Al, Manchester College of Medication, 2002. “Efficient Therapy and Headache Analysis in Care” that is Main, Neuroscience for that Main Care Company: Medical School of Virginia College, A Practical Strategy, Virginia School Richmond, Virginia, June 28, 2002.
Migraine Trust Symposium Ortho-McNeil Britain, Pharmaceutical Birmingham, June 22, 2002.
GSK, of Frustration within the Crisis/Urgent-Care Setting”, Division of Crisis Medicine Grand Rounds University Faculty of Medication, June 16, 2002. – see also: http://phobicauger78441519.pen.io
September 9-11, 2002 “Caring for Ill Regional Advisory Board AstraZeneca doctor. “Evaluating the Patient AstraZeneca Nurse Faculty Update Assembly, Tennessee, Nashville, September 27, 2002.
“Approaches to Migraine: A Summary of Therapy Methods Targeted At GA Regional Advisory Panel, AstraZeneca Beach and Maximizing, July 23, 2002.
Migraine Harder to Manage” Discussing with Evidence? CME Symposium, 44th Annual National Headache Society Assembly, Postgraduate Company for Medication, Dallas, California, July 21, 2002.
Moderator “New Improvements and Understandings within the Analysis and Treatment California, of Care Network GSK, Dallas, July 21, 2002.
“From Guides to Sufferers: Employing Medical Information to Migraine Therapy” Symposium AHS yearly assembly, Postgraduate Company for Medication, Dallas, California, July 22, 2002.
Florida, “Approaches To Local Advisory Board Meeting Jolla, July 1, 2002. “Women’s Problems In Headache”, 51st Ky School of Household Doctors, Louisville, KY May 17, 2002.
Case Reports in Frustration, program Manager, Kick on Off Plan. National Academy of Neurology Co, April-13, 2002. “Approaches to Migraine: A Summary of Therapy Methods Aimed Astra-Zeneca, at Increasing Healing Response” Local Advisory Board Meeting May 27, 2002 & FL, May 6, 2002.
“Management of Challenging Headache Sufferers – Situation Studies”, Merck Illinois, Detroit, March 28, 2002. “Headache Az, in Ladies, Top Questions” Sedona, March 16, 2002.
“Management of Migraine within the Reproductive Years” KS, Kansas Town, March 2, 2002. Public Community, “Headache/Migraine within the Perimenopausal, College of Kansas Clinic KS, March 2, 2002.
26, school Moderator Frustration Medical Swap Plan, Oklahoma Town, okay, Feb, 2002. “Women’s Problems and Headache” Population Factors Symposium, National Headache Culture, Frustration Today/ Sarasota, Bal Harbor 2002 Harbor, Jan 19, 2002.
Moderator for National Headache Society Debate Overuse: Result or Trigger Frustration Today, of Persistent Everyday Headache” / Sarasota, Bal Harbor 2002 Harbor, Jan 19, 2002.
“Women’s Problems In Grand Models Gundersen Lutheran Clinic Migraine” Health Initiative LaCrosse Nov 2, 2001.
“Hormonal Aspects Component 1”, of Migraine, 1st United States-Spanish Headache Cadiz March, 2001. Mount Pleasant, “Menstrual Migraines” Conference of The Sc Neurological Organization October 27, 2001.
“MAZE Study for Public Research” and Individual, ZOMIG Local Loudspeaker Update assembly. North Park, California, July 16, 2001 20-22 and July 13-15, 2001.
“Perimenopausal Problems in Headache”. Headache Update — 2001. FL, Buena Vista, September 19, 2001. “Global developments in Migraine Treatment: Outcomes in the LABYRINTH Survey”. The Congress of the Worldwide Headache Community Satellite Symposium, NYC, Newyork, June 30, 2001.
“Headache Testing” and Analysis. NYC, Ambassador Plan, The 10th Congress of the Worldwide Headache Community IHC 2001, Newyork, July 29, 2001.
“Prophylaxis in Migraine” Program Representative, in Frustration Treatment Welch. Annual May-10,2001 Meeting of the National School of Neurology Pa.
May-10, 2001 Medical Program, Moderator, 53rd Annual Conference of the National School of Neurology Pa. Tampa, “Hormonal Facets Of “Post and Migraine” Distressing Headache”, Yearly Frustration Symposium, College of Florida, FL, May 27-28, 2001.
Keystone National Income Assembly Launch Colorado, CORP, May 9, 2001. Issues In Migraine”. Wisconsin Advisory Board. WI, Wisconsin Dells, March 31, 2001.
“MAZE: Study for Public Research” and Individual. AstraZeneca Advisory Board. Chandler, Az, Oct 30-31, 2000.
“Understanding Migraines”. Living Nicely: A Brand New Viewpoint for Women’s Health within the 00’s. Co, Littleton, July 3, 2000. “Management of Headache”. Columbia, Medical Activity, Palmetto Clinic October 2000.
“Management of the Difficult. Tn, internal Medicine Units, College of Tennessee Clinic, Knoxville, May 18, 1999.
“Evaluating Migraine Therapy”’s Effectiveness. Migraine Nationwide Experts Assembly, Merck & Co., Ohio, Sarasota, May 15, 1999. “New Remedies of Migraine”. Tn, 16th Annual Family Primary Treatment Update Nashville, May 12, 1999.